Marken announced the launch of Solo™, their proprietary web based system used to manage the regulatory, inventory, and operational supply chain complexities of clinical trials. The system, which has been developed exclusively for Marken, is designed to manage all aspects of Marken’s global depot network including: receipt of clinical supplies and kits, dispatches, returns, warehouse movements, and QA releases. Solo™ is a secure, validated*, web-based system which is fully accessible to Marken’s clients on a 24/7 basis from any location in the world. Additionally, Marken has designed Solo™ to integrate with multiple client-directed IXR (Interactive Reporting) systems.
“We are pleased to offer this new system to our growing number of pharmaceutical clients”, said Frank Wright, Interim President, Clinical Trials Distribution at Marken.
“Solo is fit for purpose application which incorporates all of our client’s requirements for remote storage and distribution of their clinical trial supplies. We are also excited to be launching Solo as we manage an increasing number of depots around the world”. Solo™ is purpose-built to allow a high degree of customization supporting the dynamic needs of Marken’s pharmaceutical client base. The system is being launched just as Marken is opening its third fully owned and staffed depot facility in Buenos Aires, Argentina.
*validated in accordance with 21 CFR part 11
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.